3C Patch® Medicare Claims Study

Inclusion Criteria: * Medicare beneficiaries diagnosed with diabetic foot ulcer and receiving at least one treatment with the 3C Patch® System. * Eligible ulcers will be hard-to-heal, meaning that the cross-sectional area will decrease by less than 50% during a four week period prior to the first application of the 3C Patch® (percentage change in cross-sectional area determined clinically by the treating physician by estimation at examination). * Eligible ulcer's cross-sectional area will increase by less than 25% during a 4-week period prior to the first application of the 3C Patch® (percentage change determined clinically by treating physician by estimation at examination) * The cross-sectional area of the index ulcer will be ≥50 and ≤1000 mm2 at the end of the 4 week period prior to the first application of the 3C Patch® (size determined clinically by the treating physician by estimation at examination). * Participants will have the capacity to understand study procedures, and will be able to provide written informed consent. Exclusion Criteria: * Presence of sickle-cell anemia, hemophilia, thrombocytopenia (\<100x109/L) or other clinically significant blood dyscrasia * Known potential infectivity of blood products, including known HIV and hepatitis * Patient in dialysis * Clinical signs of infection of the index ulcer or reason to suspect that infection is present * Revascularization procedure in the affected limb planned, or undertaken within the 4 weeks prior to the first application of the 3C Patch® * Current treatment with cytotoxic drugs or with systemically administered glucocorticoids or other immunosuppressants * Treatment of foot ulcers with growth factors, stem cells or equivalent preparation within the 8 weeks prior to the first application of the 3C Patch® * The need for continued use of negative pressure wound therapy * Likely inability to comply with the need for follow up visits because of planned activity * Participation in another interventional clinical foot ulcer-healing trial within the 4 weeks prior to the first application of the 3C Patch® * Prior enrollment in this study * Judgement by the investigator that the patient does not have the capacity to understand the study procedures or provide written informed consent